Intellectual Property Rights

Dimminaco A.G. v. Controller of Patents and Designs

2001 SCC OnLine Cal 901; AIR 2002 Cal 255

Facts

Dimminaco applied for a patent for a process used to prepare an infectious-bursitis vaccine for poultry.
The process produced a vaccine containing a live attenuated virus.
The Patent Office rejected the application.
It reasoned that:
the final product contained a living organism;
a process yielding a living product could not result in a “manufacture”;
the invention was therefore outside patentable subject matter.
Dimminaco appealed to the Calcutta High Court.
It argued that the relevant inquiry was whether the process was new, useful and resulted in a commercially usable product, not whether living material remained in the product.

Whether a process producing a product containing living organisms can constitute patentable manufacture.
Whether biological material in the final product automatically excludes patent protection.
Whether the claimed vaccine process deserved substantive examination for novelty and usefulness.

A patentable process may involve chemical, biological or other technical treatment.
A process is not automatically excluded merely because the final product contains living material.
“Manufacture” should be interpreted in a practical commercial sense.
A process may be patentable where it:
is new;
is useful;
involves technical intervention;
results in a vendible or commercially useful product.
The existence of living organisms in the product does not by itself answer whether the human-designed process is patentable.
The patent authority must examine the actual statutory requirements rather than impose an unstated exclusion.

The claimed invention was not a claim over a naturally existing virus as found in nature.
It concerned a defined technical process for producing a usable vaccine.
Human intervention was required to:
select material;
attenuate or treat the virus;
control the process;
produce a vaccine suitable for commercial and veterinary use.
The resulting vaccine had a practical market and could be bought and sold.
The Court rejected the Patent Office’s assumption that “manufacture” necessarily means an entirely non-living article.
Many industrial and pharmaceutical processes may use biological organisms or leave living components in the final product.
Excluding all such processes would improperly prevent protection for significant biotechnology.
The proper question was whether the claimed process itself satisfied patent-law requirements.
The Patent Office had not adequately examined:
novelty;
inventive step;
industrial usefulness;
other statutory exclusions.
Instead, it had rejected the application at the threshold because of the product’s living content.
The Court therefore did not itself finally declare the patent valid.
It corrected the legal approach and directed reconsideration of the application.
The judgment became important in India because it recognised that biotechnology processes are not automatically unpatentable merely because biological life is involved.

The Calcutta High Court held that a process resulting in a product containing living organisms can constitute patentable manufacture.
The application could not be rejected solely because the vaccine contained a live virus.
The matter was remanded to the Patent Office for examination under the proper statutory tests.
Use this case for: a human-controlled process producing a commercially useful biological product is not excluded from patentability merely because the end product contains living material.